| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Greenwich Lifesciences, Inc. (GLSI) has 1 insider with recent SEC Form 4 filings, including 10 buys and 0 sells. GLSI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 5.60M | $127.89M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2022 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 500 | $18.47 | $9,235.00 | +0.2% | |
| Jan 21, 2022 | Hallock Kenneth | Director | Buy | 300 | $16.32 | $4,896.00 | - | |
| Jan 21, 2022 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 500 | $16.33 | $8,165.00 | +0.2% | |
| Jan 18, 2022 | Thompson Jaye | VP Clinical Reg. Affairs | Buy | 500 | $18.87 | $9,435.00 | +0.2% | |
| Jan 13, 2022 | Patel Snehal | CEO And CFO | Buy | 1,000 | $19.99 | $19,990.00 | - | |
| Jan 13, 2022 | Thompson Jaye | VP Clinical Reg. Affairs | Buy | 1,000 | $19.99 | $19,990.00 | +0.4% | |
| Jan 13, 2022 | Daugherty Frank Joseph | Chief Medical Officer | Buy | 1,000 | $19.99 | $19,990.00 | +1.1% | |
| Jan 3, 2022 | Patel Snehal | CEO And CFO | Buy | 2,050 | $23.82 | $48,830.80 | +0.2% | |
| Dec 14, 2021 | Patel Snehal | CEO And CFO | Buy | 1,840 | $27.17 | $49,992.43 | +0.2% | |
| Dec 14, 2021 | Daugherty Frank Joseph | Chief Medical Officer | Buy | 1,111 | $26.99 | $29,983.45 | +1.3% |